Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MACKAY MARTIN reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories director Martin Mackay received equity grants of common stock as part of his board compensation. He was awarded 1,407 shares at a reference price of $177.62 per share and a separate award of 1,438 shares at the same price. One award was granted in lieu of director service fees for the term beginning May 5, 2026. The restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders. Following these awards, one reported line shows Mackay holding 17,137 shares directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MACKAY MARTIN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K
Grant/Award	Common Stock	1,407	$177.62	$250K

Holdings After Transaction: Common Stock — 15,730 shares (Direct, null)

Footnotes (1)

The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.

Key Figures

Stock grant 1: 1,407 shares at $177.62/share Stock grant 2: 1,438 shares at $177.62/share Shares held after grant: 17,137 shares +2 more

5 metrics

Stock grant 1 1,407 shares at $177.62/share Common stock grant to director on May 8, 2026

Stock grant 2 1,438 shares at $177.62/share Second common stock grant to director on May 8, 2026

Shares held after grant 17,137 shares Direct ownership reported following one grant transaction

Vesting date trigger May 8, 2027 Restricted stock units vest by this date or before next annual meeting

Director term start May 5, 2026 Grant made in lieu of director service fees for this term

Key Terms

restricted stock units, director service fees, annual meeting of shareholders, common stock

4 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

director service fees financial

"The grant was made in lieu of director service fees for the term commencing May 5, 2026."

annual meeting of shareholders financial

"The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

common stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 04:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACKAY MARTIN

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/08/2026		A		1,438⁽¹⁾	A	$177.62	15,730	D
Common Stock	05/08/2026		A		1,407⁽²⁾	A	$177.62	17,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

2. The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Martin Mackay	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CRL director Martin Mackay report on this Form 4?

Director Martin Mackay reported receiving equity awards of Charles River Laboratories common stock as compensation. He was granted 1,407 shares and a separate 1,438-share award, both at a reference price of $177.62 per share, classified as grants rather than open-market purchases.

How many Charles River Laboratories (CRL) shares did Martin Mackay receive in each grant?

Martin Mackay received two separate stock awards. One grant covered 1,407 shares of common stock, and another grant covered 1,438 shares. Both awards are reported as compensation-related grants, not market transactions, with a transaction price reference of $177.62 per share for each grant.

At what price were Martin Mackay’s CRL stock awards valued on the grant date?

Both of Martin Mackay’s common stock awards were reported at a transaction price of $177.62 per share. This figure reflects the grant-date reference price used in the Form 4, rather than a cash purchase cost, because the awards are compensation grants, not open-market buys.

When do Martin Mackay’s CRL restricted stock units vest according to the filing?

The restricted stock units vest on the earlier of May 8, 2027, or the business day before Charles River Laboratories’ next annual meeting of shareholders. This vesting schedule applies to the unvested units referenced in the footnotes, tying vesting to either a fixed date or the next shareholder meeting.

Why did Charles River Laboratories grant stock to director Martin Mackay?

One of the grants to Martin Mackay was made in lieu of director service fees for the term beginning May 5, 2026. Instead of receiving cash fees, he received restricted stock units that vest on the earlier of May 8, 2027, or the business day before the next annual shareholder meeting.

How many CRL shares does Martin Mackay hold after these reported transactions?

After the reported grants, one transaction line shows Martin Mackay holding 17,137 Charles River Laboratories common shares directly. This figure represents his reported direct ownership following that particular grant, reflecting his equity stake after receiving the compensation-related stock award.